Heat shock protein 90 (Hsp90) chaperone complex inhibitor, Radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor

被引:46
作者
Harashima, K
Akimoto, T
Nonaka, T
Tsuzuki, K
Mitsuhashi, N
Nakano, T
机构
[1] Gunma Univ, Grad Sch Med, Dept Radiat Oncol, Gunma 3718511, Japan
[2] Gunma Univ, Grad Sch Med, Dept Neurophysiol, Gunma, Japan
[3] Tokyo Womens Med Univ, Dept Radiol, Tokyo, Japan
关键词
Hsp90 chaperone complex; radicicol; radiation; prostate cancer; LNCaP;
D O I
10.1080/09553000400029460
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Until now, there has not been enough information on how androgens or androgen deprivation may influence the response of cancer cells to radiation. In this study, the effect of dihydrotestosterone (DHT) on cellular proliferative activity and radiosensitivity was examined in a hormone-sensitive human prostate cancer cell line, LNCaP. In addition, the study also examined how a heat shock protein 90 (Hsp90) chaperone complex inhibitor modified the effect of DHT on the radiosensitivity of the cells, because binding of the androgen receptor (AR) to Hsp90 is required to maintain the stability and functioning of AR. The hormone-sensitive human prostate cancer cell line, LNCaP, was used. Radicicol was used as one of the known Hsp90 chaperone complex inhibitors, and the cells were incubated in the presence of this compound at a concentration of 500 nM. Cellular radiosensitivity was determined by the clonogenic assay; the changes in the protein expression were examined by Western blotting or immunofluorescence. DHT at a concentration of 1 nM caused enhancement of the proliferative activity and reduction of the radiosensitivity of the cells. Radicicol at a concentration of 500 nM abolished the DHT-induced decrease in cellular radiosensitivity and potentiated the radiation-induced cell killing synergistically. Consistent with the changes in the cellular radiosensitivity, radicicol degraded AR, Raf-1 and HER2/neu via reduced binding of AR to Hsp90, although selective degradation of HER2/neu caused by Herceptin, a monoclonal antibody against HER2, did not affect the cellular radiosensitivity. The results suggest that the Hsp90 chaperone complex may be a potential molecular target for potentiation of radiation-induced cell killing in a hormone-sensitive prostate cancer cell line.
引用
收藏
页码:63 / 76
页数:14
相关论文
共 30 条
[1]  
BERCHEM GJ, 1995, CANCER RES, V55, P735
[2]   Quantitative biomarker analysis of synovial gene expression by real-time PCR [J].
Boyle, DL ;
Rosengren, S ;
Bugbee, W ;
Kavanaugh, A ;
Firestein, GS .
ARTHRITIS RESEARCH & THERAPY, 2003, 5 (06) :R352-R360
[3]   C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation [J].
Cardozo, CP ;
Michaud, C ;
Ost, MC ;
Fliss, AE ;
Yang, E ;
Patterson, C ;
Hall, SJ ;
Caplan, AJ .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 410 (01) :134-140
[4]  
Chen Y, 1996, CELL GROWTH DIFFER, V7, P1571
[5]   Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides [J].
Eder, IE ;
Culig, Z ;
Ramoner, R ;
Thurnher, M ;
Putz, T ;
Nessler-Menardi, C ;
Tiefenthaler, M ;
Bartsch, G ;
Klocker, H .
CANCER GENE THERAPY, 2000, 7 (07) :997-1007
[6]   Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer [J].
Gao, N ;
Zhang, Z ;
Jiang, BH ;
Shi, XL .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 310 (04) :1124-1132
[7]   Mechanism of antiandrogen action:: Key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor [J].
Georget, V ;
Térouanne, B ;
Nicolas, JC ;
Sultan, C .
BIOCHEMISTRY, 2002, 41 (39) :11824-11831
[8]   Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines [J].
Guo, CH ;
Luttrell, LM ;
Price, DT .
JOURNAL OF UROLOGY, 2000, 163 (03) :1027-1032
[9]   Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 [J].
Hanks, GE ;
Pajak, TF ;
Porter, A ;
Grignon, D ;
Brereton, H ;
Venkatesan, V ;
Horwitz, EM ;
Lawton, C ;
Rosenthal, SA ;
Sandler, HM ;
Shipley, WU .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3972-3978
[10]   Early prostate cancer: clinical decision-making [J].
Jani, AB ;
Hellman, S .
LANCET, 2003, 361 (9362) :1045-1053